SCHEDULE: Millennium Entities Report Ardelyx Stake

Millennium Management LLC and affiliated entities have filed a Schedule 13G, reporting a combined beneficial ownership of 5.7% of Ardelyx, Inc. common stock as of June 30, 2026.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, indicating their beneficial ownership of Ardelyx, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 14,200,773 shares of Ardelyx, Inc. common stock.
• This represents 5.7% of the class of securities outstanding.
• Integrated Core Strategies (US) LLC holds 12,030,115 shares, representing 4.8% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 14,200,773 shares, representing 5.7% of the class.
• The filing clarifies that the securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
• The filing is an amendment (Amendment No. 2) to a previous filing.
• The reporting persons certify that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes without providing operational or financial performance updates.

Positives

• The filing provides transparency regarding significant beneficial ownership of Ardelyx, Inc. by established investment entities.
• The joint filing agreement ensures coordinated reporting and compliance with SEC regulations.

Negatives

• The filing does not contain any financial performance data or operational updates for Ardelyx, Inc.

Risks

• Potential for increased market activity or influence by the reporting entities on Ardelyx, Inc.'s stock price.
• The concentration of ownership could lead to shifts in corporate strategy if the reporting entities decide to exert influence.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The reporting persons certify that the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates a notable position held by Millennium entities in Ardelyx, a biopharmaceutical company.

Stakeholder Impact

• Shareholders: Increased institutional ownership may influence stock liquidity and trading dynamics.
• Management of Ardelyx, Inc.: May need to engage with significant institutional holders regarding strategy and governance.
• Competitors: Awareness of significant investment positions by major financial players in the biopharmaceutical sector.

Next Steps

• Continued monitoring of Ardelyx, Inc. by the reporting entities.
• Potential future amendments to the Schedule 13G if ownership levels change significantly.

Key Dates

Keywords

Ardelyx, Schedule 13G, Beneficial Ownership, Millennium Management, Integrated Core Strategies, Investment Management, SEC Filing, Common Stock